Year-end report 2025

MSAB reported record 2025 results with Q4 net sales of SEK 140.6m (up 19.6% YoY; currency-adjusted +29.5%) and FY net sales of SEK 461.8m (up 14.1%; currency-adjusted +19.7%). Operating profit (EBIT) was SEK 40.6m in Q4 (28.9% margin) and SEK 67.8m for the year (14.7% margin), profit after tax SEK 49.2m, EPS SEK 2.66, and operating cash flow SEK 101.9m; the Board proposes a SEK 1.60 per share dividend (two payments, ~60% of profit). Management cites strong demand for its XRY Pro forensic product, regional strength in EMEA and APAC, near-term investments that may pressure margins, and continued optimism for growth in 2026.

Analysis

Market structure: MSAB’s results show durable pricing power (gross margin 93%) and accelerating top-line with Q4 +19.6% YoY (currency adj +29.5%), which benefits specialist forensic-software vendors, authorized distributors, and adjacent training/certification providers. Losers include low-end extraction tool vendors and manual-forensics consultancies losing share to scalable software; public-sector budget volatility (US shutdown impact) remains a gating factor. Cross-asset: stronger cash flow (operating CF SEK 102m) reduces refinancing risk and should compress CDS spreads for Nordic small-cap tech; expect muted FX sensitivity (revenues global, reporting SEK) but watch USD-denominated contract timing that can move FX hedges and short-dated rates exposure.

Risk assessment: Tail risks are regulatory (export controls or legal limits on extraction techniques), a major US contract cancellation, or a zero-day vulnerability that undermines product trust; probability medium but impact high (>-30% rev hit). Near-term (days–weeks) sensitivity centers on guidance/contract announcements and dividend confirmation; medium-term (3–12 months) depends on military sector wins and R&D investments compressing margins. Hidden dependency: distributor concentration in certain APAC/EMEA markets and reliance on a handful of large law-enforcement contracts; loss of one could swing quarterly revenue by >10%. Key catalysts: government procurement awards (30–180 days), product certifications, and US budget clarity.

trade implications: Direct long: buy MSAB B (3–5% net exposure) on the thesis of continued 15–20% currency-adjusted growth and margin expansion to >15% FY; set stop-loss at -20% and add on confirmed military contract(s). Options: if liquid, implement a 12-month 25% OTM call spread sized to 2% portfolio to cap downside while capturing upside from contract wins. Pair trade: long MSAB B vs short HACK or CIBR (ratio 3:1) to isolate forensic-software upside vs broad cyber names; rebalance if spread widens/narrows >15%. Rotate 2–3% into defence-exposed names (e.g., SAAB B) on pullbacks ahead of procurement cycles.

contrarian angles: Consensus underestimates durability of MSAB’s 93% gross margin and sticky SaaS-like attach rates from training/certification—if sustained, valuation re-rate is possible even with increased R&D. Conversely, the market may underprice regulatory risk: a single adverse ruling or export restriction could cause >25% downside quickly. Historical parallels include Cellebrite’s episodic contract/regulatory volatility—outcomes diverge based on contract diversification and certifications; watch for unintended consequence that heavy military focus could concentrate revenue cyclicality rather than smooth growth.

Key Decisions for Investors

• Establish a 3–5% long position in MSAB B over the next 2–6 weeks; increase to 6–8% only if next quarterly organic currency-adjusted growth >15% and EBIT margin sustains >14.5%. Use a hard stop-loss at 20% below entry and trim half position on a 30% run-up.
• If liquid, buy a 12-month MSAB B call spread (buy 25% OTM, sell 50% OTM) sized to 2% of portfolio to cap downside and capture upside from expected procurement wins within 6–12 months; if no options, replicate via 2% CFD long with defined stop-loss.
• Implement a relative-value pair: long MSAB B (3%) vs short HACK (1%) or CIBR (1%) to isolate forensic-software outperformance; unwind if spread moves adversely by >15% or on confirmation of major US contract award/loss within 60 days.
• Rotate 2–3% into defence/military-exposed equities (e.g., SAAB B on Nasdaq Stockholm) on any pullback >5% to play stated military-sector strategy; hold 6–12 months and reassess after contract announcements.
• Within 30–60 days, monitor three binary triggers: (1) US federal contracting/payment clarity post-shutdown, (2) any announced export-control or legal restrictions on extraction tools, and (3) disclosure of material distributor concentration (>10% revenue). Liquidate or cut exposure by at least 50% if any trigger is breached.